Abstract:Research demonstrates that the neural mechanisms underlying synaptic plasticity and learning and memory involve mobilization of AMPA-type neurotransmitter receptors at glutamatergic synaptic contacts, and that these mechanisms are targeted during neurodegenerative disease. Strengthening neural transmission occurs with insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) into synapses while weakening results from receptor withdrawal. A key player in the trafficking of AMPARs during plasticity and learning is the brain-derived neurotrophic factor (BDNF) signaling system. BDNF is a neurotrophic factor that supports neuronal growth and is required for learning and memory. Significantly, a primary feature of many neurodegenerative diseases is a reduction in BDNF protein as well as disrupted neuronal surface expression of synaptic AMPARs. The resulting weakening of synaptic contacts leads to synapse loss and neuronal degeneration that underlies the cognitive impairment and dementia observed in patients with progressive neurodegenerative disease such as Alzheimer's. In the face of these data, one therapeutic approach is to increase BDNF bioavailability in brain. While this has been met with significant challenges, the results of the research have been promising. In spite of this, there are currently no clinical trials to test many of these findings on patients. Here, research showing that BDNF drives AMPARs to synapses, AMPAR trafficking is essential for synaptic plasticity and learning, and that neurodegenerative disease results in a significant decline in BDNF will be reviewed. The aim is to draw attention to the need for increasing patient-directed clinical studies to test the possible benefits of increasing levels of neurotrophins, specifically BDNF, to treat brain disorders. Much is known about the cellular mechanisms that underlie learning and memory in brain. It can be concluded that signaling by neurotrophins like BDNF and AMPA-type glutamate receptor synaptic trafficking are fundamental to these processes. Data from animal models and patients reveal that these mechanisms are adversely targeted during neurodegenerative disease and results in memory loss and cognitive decline. A brief summary of our understanding of these mechanisms indicates that it is time to apply this knowledge base directly to development of therapeutic treatments that enhance neurotrophins for brain disorders in patient populations.

Indirect influence on the BDNF/TrkB receptor signaling pathway via GPCRs, an emerging strategy in the treatment of neurodegenerative disorders

Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents

TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury

Regulation of TrkB cell surface expression—a mechanism for modulation of neuronal responsiveness to brain-derived neurotrophic factor

BDNF-TrkB Signaling in Mitochondria: Implications for Neurodegenerative Diseases

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Targeting TrkB-PSD-95 coupling to mitigate neurological disorders

Neurobiology of local and intercellular BDNF signaling

TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions

Targeting brain-derived neurotrophic factor in the treatment of neurodegenerative diseases: A review

Regulation of BDNF-TrkB Signaling and Potential Therapeutic Strategies for Parkinson's Disease

Neurotrophin-targeted therapeutics: a gateway to cognition and more?

Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications.

Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease

Actions of the TrkB Agonist Antibody ZEB85 in Regulating the Architecture and Synaptic Plasticity in Hippocampal Neurons

The Rab11-regulated endocytic pathway and BDNF/TrkB signaling: Roles in plasticity changes and neurodegenerative diseases

Differential Effects of Transient and Sustained Activation of BDNF‐TrkB Signaling

Discovery of a pocket network on the domain 5 of the TrkB receptor – A potential new target in the quest for the new ligands

Emphasizing roles of BDNF promoters and inducers in Alzheimer's disease for improving impaired cognition and memory

BDNF and synaptic plasticity, cognitive function, and dysfunction.

BDNF-Regulated Modulation of Striatal Circuits and Implications for Parkinson's Disease and Dystonia